Results 121 to 130 of about 48,976 (264)

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Engineered artificial antigen-presenting cells for tumor immunotherapy: Design strategies, clinical applications, and translational challenges. [PDF]

Mater Today Bio
Cai H, Zhao Y, Cai Y, Luo X, Li J, Wu Y, Yang J, Wang C, Zhang Y, Ding H, Cheng S, Wang Y.   +11 more
europepmc   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Methodological Insights Into T-Cell Activation: CD3/CD28 Versus PMA/Ionomycin Stimulation. [PDF]

Eur J Immunol
Abdulhaqov N, Melo LTA, Meinert I, Fricke S, Simeoni L.   +4 more
europepmc   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer: Which Is the Most Effective? [PDF]

Cancer Med
Wang L, Cao Y, Ren Y, Zhang Y, Wang L.
europepmc   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. [PDF]

Cancer Immunol Res
Tang E, Hu Y, Cao G, Nguyen DT, Asby NW, Aboelella NS, Ruiz HA, Cai X, Zhang W, Zhao Y, Xie L, Chen X, Bishop MR, Riedell PA, LaBelle JL, Kline JP, Huang J.   +16 more
europepmc   +1 more source

UBE2C‐Mediated CD147‐CTLA‐4 Axis Promotes T Cell Exhaustion and Immunosuppressive Microenvironment in Bladder Cancer

Cancer Science, EarlyView.
UBE2C upregulates cellular CD147 and enhances its release into the tumor microenvironment both as soluble CD147 (sCD147) and packaged within tumor‐derived exosomes. These CD147‐bearing signals induce T‐cell exhaustion, marked by elevated CTLA‐4 expression and reduced secretion of effector cytokines (IFN‐γ, TNF‐α, TGF‐β), ultimately diminishing CD8+ T ...
Xuwei Hong, Ting Hong, Xinyu Liu, Peixiu Yao, Weiqiang Lin, Guoyuan Liu, Huihong Guan, Yonghai Zhang   +7 more
wiley   +1 more source

Discovery of co-stimulatory anti-CD28 VHHs for developing cancer immune therapeutic anti-tumor/CD3/CD28 trispecific T cell engager. [PDF]

Front Immunol
Wang H, Zhao R, Liu M, Jiang T, Sun D, Chi L, Huang Y, Lu Z, Yun Y, Wang X.   +9 more
europepmc   +1 more source